Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Centre de Recherche en Sante de Nouna, Burkina Faso | OTHER_GOV |
| Bill and Melinda Gates Foundation | OTHER |
Not provided
Not provided
Not provided
Globally, childhood mortality has shown a promising downward trend in recent years, however, many sub-Saharan countries still have relatively high child mortality rates. In previous studies within Niger, Tanzania, and Malawi, mass azithromycin treatment to children aged 1-59 months old effectively reduced all-cause childhood mortality. A similar study will be conducted in Burkina Faso to replicate the results of mass azithromycin treatment.
The investigators propose an individually randomized placebo-controlled trial alongside the MORDOR II Burkina Faso trial to evaluate the effect of a single dose of azithromycin (20 mg/kg) on potential mediators of the effect of azithromycin on all-cause mortality. Many questions surround the mechanism behind azithromycin's effect on reducing childhood mortality. Further questions exist regarding antibiotic resistance and how mass antibiotic administration can impact intestinal microflora. The goal of this study is to demonstrate the changes in the gut microbiome after antibiotic administration and to measure the growth of children after receiving a single dose of azithromycin. Additionally we will measure resistance markers, inflammatory markers, and IgA-bound bacteria. We hypothesize that a single dose of azithromycin will lead to a significant increase in child growth and that the gut microbiome will be significantly different in children who received azithromycin compared to those who received placebo.
Objectives:
The study will be conducted in Nouna Town in northwestern Burkina Faso.
The investigators' previous MORDOR I research demonstrated a significant reduction in all-cause child mortality after biannual mass azithromycin distribution. In three sub-Saharan Africa countries, (including Niger, Tanzania, and Malawi) mass azithromycin treatment over 2 years resulted in a 14% reduction in child mortality. Moreover, 1 in 5-6 deaths were shown to be averted within Niger alone1. Similar findings were demonstrated in a previous study for trachoma control in Ethiopia with mass azithromycin distribution. This study in rural Ethiopia noted a nearly 50% decrease in all-cause childhood mortality5. However, neither of these studies evaluated the longitudinal impact azithromycin has on the gut microbiome. The MORDOR II trial in Burkina Faso will further evaluate the efficacy of biannual azithromycin treatment. The under-5 child mortality rate in Burkina Faso is approximately 110 per 1,000 live births. Major causes of child mortality in this area are infectious mostly due to malaria, diarrhea, and upper respiratory tract infections. In addition, malnutrition contributes to a high burden of child mortality and morbidity within this region as well. By treating underlying conditions, the use of routine antibiotic treatment could reduce diverse health outcomes leading to morbidity and mortality. The investigative team proposes to conduct this study alongside the MORDOR II trial in the town of Nouna where a majority of childhood deaths are attributable to infectious causes and malnutrition.
The World Health Organization is considering adopting the presumptive use of azithromycin and other antibiotics as a recommendation to reduce childhood mortality in areas with a high infectious disease burden2. Many questions remain unanswered surrounding the use of mass antibiotic treatment in areas with high child morbidity and mortality. This study will add to the current knowledge of mass azithromycin distribution from our previous MORDOR I research. The investigators propose to evaluate how azithromycin will impact childhood growth and to assess the changes that occur in the intestinal microbiome following a single dose of azithromycin treatment. The goal is to contribute more scientific literature that could assist future guidelines regarding antibiotic use.
The role of antibiotics on child growth is unclear. Recent studies indicate that antibiotic use could impact child growth, but a previous study in Niger failed to find a statistically significant correlation between antibiotic treatment with azithromycin and stunting, underweight, or MUAC of pre-school aged children. Longitudinal studies have been recommended to further investigate the role of antibiotics on child growth6. Meanwhile some studies suggest antibiotics may create modifications in the gut microbiota impacting nutrient absorption and weight gain7.The investigative team proposes to measure child growth through anthropometric measurements longitudinally over a 6-month period to see if azithromycin treatment impacts child development. We hypothesize that children receiving a dose of azithromycin will have more growth and development in terms of height, weight, and mid-upper arm circumference compared to children who receive placebo.
The investigators propose a longitudinal study designed to improve our knowledge about the changes in the intestinal microbiome following the course of a single dose of antibiotic in a setting with high childhood mortality and morbidity. More specifically, we propose to follow 500 children for a 6-month time period that are between the ages of 8 days old and 59 months old. Children in this age bracket are at the highest risk for mortality from infectious causes, and furthermore, they are at the highest risk for malnutrition. This group of children would receive the greatest benefit from this intervention. The causal changes in the microbiome are vastly understudied in regards to changes in the gut microbiome following a course of antibiotics. The investigators hypothesize that children receiving a dose of azithromycin will have a higher prevalence of pneumococcal resistance in nasopharyngeal samples, decreased bacterial diversity, and a higher likelihood of identification of bacterial resistance genes in stool and nasopharyngeal samples.
A small group of 50 children (25 per arm) will be followed more intensely within the first 2 weeks of treatment to evaluate macrolide resistance. The investigators hypothesize that children receiving azithromycin will have a greater presence of macrolide genetic resistant determinants.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Azithromycin | Active Comparator | A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old. |
|
| Placebo | Placebo Comparator | A single dose of placebo will be administered to children between the ages of 8 days and 59 months old. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Azithromycin | Drug | Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin. |
| Measure | Description | Time Frame |
|---|---|---|
| Intestinal Microbial Diversity | The primary outcome of the study was pre-specified as α-diversity (inverse Simpson's) at the genus level, expressed in effective number. The minimum of Simpson's index of diversity is 0, there is no maximum. Higher Simpson's index of diversity means more diverse. There are no subscales. | 6 months |
| Macrolide Resistance | Presence of macrolide genetic resistance determinants measured using DNA-seq from rectal swabs from 450 children. Macrolide resistance is defined by resistance to erythromycin or clarithromycin. We compare the read numbers of macrolide resistance in each treatment group. A higher read number indicates more resistance. | 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Weight Over Time | WAZ. Weight will be measured at all follow-ups and weight-for-age z-scores will be calculated. Weight measured in kg. | 180 days post-treatment |
| Change in Height Over Time |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Catherine Oldenburg, PhD | University of California, San Francisco | Principal Investigator |
| Ali Sie, MD, PhD | Centre de Recherce en Sante de Nouna | Principal Investigator |
| Tom Lietman, MD | University of California, San Francisco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre de Recherche en Sante de Nouna | Nouna | Burkina Faso |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38227963 | Derived | Doan T, Liu Z, Sie A, Dah C, Bountogo M, Ouattara M, Coulibaly B, Kiemde D, Zonou G, Nebie E, Brogdon J, Lebas E, Hinterwirth A, Zhong L, Chen C, Zhou Z, Porco T, Arnold BF, Oldenburg CE, Lietman TM. Gut Microbiome Diversity and Antimicrobial Resistance After a Single Dose of Oral Azithromycin in Children: A Randomized Placebo-Controlled Trial. Am J Trop Med Hyg. 2024 Jan 16;110(2):291-294. doi: 10.4269/ajtmh.23-0651. Print 2024 Feb 7. | |
| 35944061 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Azithromycin | A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old. Azithromycin: Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin. |
| FG001 | Placebo | A single dose of placebo will be administered to children between the ages of 8 days and 59 months old. Placebo: Oral suspension of placebo for azithromycin |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Azithromycin | A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old. Azithromycin: Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Intestinal Microbial Diversity | The primary outcome of the study was pre-specified as α-diversity (inverse Simpson's) at the genus level, expressed in effective number. The minimum of Simpson's index of diversity is 0, there is no maximum. Higher Simpson's index of diversity means more diverse. There are no subscales. | Analysis was done 5-pooled. | Posted | Mean | Standard Deviation | index score | 6 months |
|
14 days following azithromycin or placebo treatment. Deaths were assessed up to 180 days post-treatment. Adverse Events were assessed 14 days following azithromycin or placebo treatment
We report adverse events and clinic visits during the 2-week period immediately after treatment to better understand the safety and short-term impact of azithromycin compared with placebo in young children.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Azithromycin | A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old. Azithromycin: Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Fever (self-report) | General disorders | Systematic Assessment | 14 days following azithromycin or placebo treatment among children aged 0-59 months |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pr Thomas Lietman | UCSF FI Proctor | (415) 476-1442 | tom.lietman@ucsf.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jul 1, 2021 | Jan 6, 2023 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Oct 20, 2021 | Jan 6, 2023 | SAP_001.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017963 | Azithromycin |
| ID | Term |
|---|---|
| D004917 | Erythromycin |
| D018942 | Macrolides |
| D061065 | Polyketides |
| D007783 | Lactones |
| D009930 |
Not provided
Not provided
Individually randomized placebo-controlled trail of azithromycin vs. placebo to establish the efficacy and safety of azithromycin.
Not provided
Not provided
Quadruple: (Participant, Care Provider, Investigator, Outcomes Assessor)
|
| Placebo | Drug | Oral suspension of placebo for azithromycin |
|
Height or length will be measured at all follow-ups and height-for-age z-scores will be calculated.
| 180 days post-treatment |
| Number of Participants With Infantile Hypertrophic Pyloric Stenosis | 6 months |
| Mortality | Vital status will be assessed at all follow-up time points. Mortality will be defined as death within the study period. Date of death will be collected. | 180 days post-treatment |
| Malaria Status | Number of Participants Positive for Malaria. Blood smears (thin and thick) for malaria will be collected at all follow-ups to determine malaria infection status. | 180 days post-treatment |
| Adverse Events | Caregivers will be asked if the child has been taken to the health post since the last visit and why | 14 days post-treatment |
| Genotypic Resistance | Total resistance read numbers in 12 classes: Aminoglycosides, Cationic antimicrobial peptides, Elfamycins, MLS, Metronidazole, Multi-drug resistance, Phenicol, Rifampin, Sulfonamides, Tetracyclines, Trimethoprim, and Beta-lactams. We compare the read numbers of macrolide resistance in each treatment group. A higher read number indicates more resistance. | 180 days post-treatment |
| Inflammatory Marker Changes | Measured by C-reactive protein | 6 months |
| IgA-bound Bacteria From Small Intestine Changes | Measured using BugFACS from whole blood and stool | 180 days post-treatment |
| Nutritional Status | To be measured using mid-upper arm circumference | 180 days post-treatment |
| Acute Modulation of the Gut Microbiome | Next generation sequencing | 2 weeks post-treatment |
| L-1 Norm Distance on Bacterial Reads (Intestinal) | L-1 norm distance on bacterial reads (intestinal) from rectal swabs of 50 children. L1-norm distance on bacterial reads (intestinal) - L1 norm is equivalent to Shannon's diversity. Shannon's Alpha Diversity combines richness and diversity. Shannon's index of diversity (alpha diversity) measures both the number of species and the inequality between species abundances. A large value is given by the presence of many species with well balanced abundances. | 2 weeks post-treatment |
| L-2 Norm Distance on Bacterial Reads (Intestinal) | L-2 norm distance on bacterial reads (intestinal) from rectal swabs of 450 children. L2-norm distance on bacterial reads (intestinal) - L2 norm is equivalent to Simpson's diversity. Simpson's Alpha Diversity were obtained at Baseline and Post-treatment in this study. The minimum of Simpson's index of diversity is 0, there is no maximum. Higher Simpson's index of diversity means more diverse. There are no subscales. | 2 weeks post-treatment |
| Changes in Normalized Reads for Campylobacter Species | Reduce in normalized reads for Campylobacter species using DNA-seq from rectal swabs of 450 children. We compare the read numbers of Campylobacter species in each treatment group. Campylobacter is associated with disease. Reduction in Campylobacter species burden may reduce diarrhea-related mortality. | 2 weeks post-treatment |
| Resistome | Chao1 total resistance gene determinant richness using DNA-seq from rectal swabs of 450 children. We calculated Chao1 total resistance gene determinant richness across arms. Species richness is the simplest measure of biodiversity and is just a count of the number of different species in a given area. | 2 weeks post-treatment |
| Derived |
| Coulibaly B, Kiemde D, Zonou G, Sie A, Dah C, Bountogo M, Brogdon J, Hu H, Lebas E, Porco TC, Doan T, Lietman TM, Oldenburg CE. Effect of Single-dose Azithromycin on Pneumococcal Carriage and Resistance: A Randomized Controlled Trial. Pediatr Infect Dis J. 2022 Sep 1;41(9):728-730. doi: 10.1097/INF.0000000000003585. Epub 2022 May 23. |
| 34465327 | Derived | Coulibaly B, Sie A, Dah C, Bountogo M, Ouattara M, Compaore A, Nikiema M, Tiansi JN, Sibiri ND, Brogdon JM, Lebas E, Doan T, Porco TC, Lietman TM, Oldenburg CE. Effect of a single dose of oral azithromycin on malaria parasitaemia in children: a randomized controlled trial. Malar J. 2021 Aug 31;20(1):360. doi: 10.1186/s12936-021-03895-9. |
| 33731058 | Derived | Sie A, Coulibaly B, Dah C, Bountogo M, Ouattara M, Compaore G, Brogdon JM, Godwin WW, Lebas E, Doan T, Arnold BF, Porco TC, Lietman TM, Oldenburg CE. Single-dose azithromycin for child growth in Burkina Faso: a randomized controlled trial. BMC Pediatr. 2021 Mar 17;21(1):130. doi: 10.1186/s12887-021-02601-7. |
| BG001 | Placebo | A single dose of placebo will be administered to children between the ages of 8 days and 59 months old. Placebo: Oral suspension of placebo for azithromycin |
| BG002 | Total | Total of all reporting groups |
| months |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Mother's age | Mean | Inter-Quartile Range | years |
|
| Mother's education | Count of Participants | Participants |
|
| Mid-upper arm circumference, cm | Mean | Inter-Quartile Range | cm |
|
| Weight, kg | Mean | Inter-Quartile Range | kg |
|
| Height, cm | Mean | Standard Deviation | cm |
|
| Weight-for-height Z-score | Nutritional status as determined by weight-for-height Z-score vs. Placebo household Weight-for-height Z-score in each antibiotic group compared with placebo 4 weeks after last antibiotic dose Weight-for-height Z (WHZ) scores were calculated based on the 2006 World Health Organization (WHO) standards. The mean of the 2006 population standards is 0. Lower standard deviations = worse outcomes. A cutoff of < -2 means moderately wasted (WHZ). A cutoff of < -3 means wasted (WHZ). | Mean | Standard Deviation | score |
|
| Height-for-age Z-score | Nutritional status as determined by height-for-age Z-score Height-for-age Z-score in each antibiotic group compared with placebo 4 weeks after last antibiotic dose Height-for-age Z (HAZ) score were calculated based on the 2006 World Health Organization (WHO) standards. The mean of the 2006 population standards is 0. Lower standard deviations = worse outcomes. A cutoff of < -2 means moderately stunted (HAZ). A cutoff of < -3 means severely stunted (HAZ). | Mean | Standard Deviation | score |
|
| Weight-for-age Z-score | Nutritional status as determined by weight-for-age Z-score vs. Placebo household Weight-for-age Z-score in each antibiotic group compared with placebo 4 weeks after last antibiotic dose Weight-for-age Z-score (WAZ) scores were calculated based on the 2006 World Health Organization (WHO) standards. The mean of the 2006 population standards is 0. Lower standard deviations = worse outcomes. A cutoff of < -2 means moderately underweight (WAZ). A cutoff of < -3 means severely underweight (WAZ). | Mean | Standard Deviation | score |
|
| Wasted (WHZ < -2) | Count of Participants | Participants |
|
| Stunted (HAZ < -2) | Count of Participants | Participants |
|
| Underweight (WAZ < -2) | Count of Participants | Participants |
|
| Mid-upper arm circumference < 12.5 cm | Count of Participants | Participants |
|
| Malaria RDT Positive | Count of Participants | Participants |
|
| OG001 | Placebo | A single dose of placebo will be administered to children between the ages of 8 days and 59 months old. Placebo: Oral suspension of placebo for azithromycin |
|
|
| Primary | Macrolide Resistance | Presence of macrolide genetic resistance determinants measured using DNA-seq from rectal swabs from 450 children. Macrolide resistance is defined by resistance to erythromycin or clarithromycin. We compare the read numbers of macrolide resistance in each treatment group. A higher read number indicates more resistance. | We were able to follow up with 221 patients in the azithromycin arm and 208 children in the placebo arm. | Posted | Mean | Standard Deviation | number of reads | 2 weeks |
|
|
|
| Secondary | Change in Weight Over Time | WAZ. Weight will be measured at all follow-ups and weight-for-age z-scores will be calculated. Weight measured in kg. | Posted | Mean | Standard Deviation | kg | 180 days post-treatment |
|
|
|
| Secondary | Change in Height Over Time | Height or length will be measured at all follow-ups and height-for-age z-scores will be calculated. | Posted | Mean | Standard Deviation | cm | 180 days post-treatment |
|
|
|
| Secondary | Number of Participants With Infantile Hypertrophic Pyloric Stenosis | Posted | Count of Participants | Participants | 6 months |
|
|
|
| Secondary | Mortality | Vital status will be assessed at all follow-up time points. Mortality will be defined as death within the study period. Date of death will be collected. | Posted | Count of Participants | Participants | 180 days post-treatment |
|
|
|
| Secondary | Malaria Status | Number of Participants Positive for Malaria. Blood smears (thin and thick) for malaria will be collected at all follow-ups to determine malaria infection status. | Posted | Count of Participants | Participants | 180 days post-treatment |
|
|
|
| Secondary | Adverse Events | Caregivers will be asked if the child has been taken to the health post since the last visit and why | Posted | Count of Participants | Participants | 14 days post-treatment |
|
|
|
| Secondary | Genotypic Resistance | Total resistance read numbers in 12 classes: Aminoglycosides, Cationic antimicrobial peptides, Elfamycins, MLS, Metronidazole, Multi-drug resistance, Phenicol, Rifampin, Sulfonamides, Tetracyclines, Trimethoprim, and Beta-lactams. We compare the read numbers of macrolide resistance in each treatment group. A higher read number indicates more resistance. | We were able to follow up with 200 children in the azithromycin group and 191 children in the placebo group. | Posted | Number | number of reads | 180 days post-treatment |
|
|
|
| Secondary | Inflammatory Marker Changes | Measured by C-reactive protein | The Inflammatory marker changes data is not collected in this study | Posted | 6 months |
|
|
| Secondary | IgA-bound Bacteria From Small Intestine Changes | Measured using BugFACS from whole blood and stool | Data is not collected | Posted | 180 days post-treatment |
|
|
| Secondary | Nutritional Status | To be measured using mid-upper arm circumference | Posted | Mean | Standard Deviation | cm | 180 days post-treatment |
|
|
|
| Secondary | Acute Modulation of the Gut Microbiome | Next generation sequencing | No data was collected/analyzed. | Posted | 2 weeks post-treatment |
|
|
| Secondary | L-1 Norm Distance on Bacterial Reads (Intestinal) | L-1 norm distance on bacterial reads (intestinal) from rectal swabs of 50 children. L1-norm distance on bacterial reads (intestinal) - L1 norm is equivalent to Shannon's diversity. Shannon's Alpha Diversity combines richness and diversity. Shannon's index of diversity (alpha diversity) measures both the number of species and the inequality between species abundances. A large value is given by the presence of many species with well balanced abundances. | Posted | Mean | Standard Deviation | Index score | 2 weeks post-treatment |
|
|
|
| Secondary | L-2 Norm Distance on Bacterial Reads (Intestinal) | L-2 norm distance on bacterial reads (intestinal) from rectal swabs of 450 children. L2-norm distance on bacterial reads (intestinal) - L2 norm is equivalent to Simpson's diversity. Simpson's Alpha Diversity were obtained at Baseline and Post-treatment in this study. The minimum of Simpson's index of diversity is 0, there is no maximum. Higher Simpson's index of diversity means more diverse. There are no subscales. | Posted | Mean | Standard Deviation | Index score | 2 weeks post-treatment |
|
|
|
| Secondary | Changes in Normalized Reads for Campylobacter Species | Reduce in normalized reads for Campylobacter species using DNA-seq from rectal swabs of 450 children. We compare the read numbers of Campylobacter species in each treatment group. Campylobacter is associated with disease. Reduction in Campylobacter species burden may reduce diarrhea-related mortality. | Posted | Number | number of reads | 2 weeks post-treatment |
|
|
|
| Secondary | Resistome | Chao1 total resistance gene determinant richness using DNA-seq from rectal swabs of 450 children. We calculated Chao1 total resistance gene determinant richness across arms. Species richness is the simplest measure of biodiversity and is just a count of the number of different species in a given area. | Posted | Mean | Standard Deviation | number of species | 2 weeks post-treatment |
|
|
|
| 0 |
| 221 |
| 0 |
| 221 |
| 44 |
| 221 |
| EG001 | Placebo | A single dose of placebo will be administered to children between the ages of 8 days and 59 months old. Placebo: Oral suspension of placebo for azithromycin | 0 | 209 | 0 | 209 | 42 | 209 |
|
| Abdominal pain | General disorders | Systematic Assessment | 14 days following azithromycin or placebo treatment |
|
| Vomiting | Gastrointestinal disorders | Systematic Assessment | 14 days following azithromycin or placebo treatment among children |
|
| Diarrhea | Gastrointestinal disorders | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
|
| Skin rash | Skin and subcutaneous tissue disorders | Systematic Assessment | 14 days following azithromycin or placebo treatment |
|
Not provided
Not provided
Not provided
| Organic Chemicals |